NYSE · Healthcare
Genpact LTD (G)
As-reported financials and recent SEC filings for Genpact LTD, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$5.08B
Net income
$552.5M
Net margin
10.9%
Diluted EPS
$3.13
ROE
21.7%
P/E (TTM)
8.8×
Market cap
$4.84B
Debt / equity
0.5×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.08B | $4.77B | $4.48B | $4.37B | $4.02B |
| Gross profit | $1.83B | $1.69B | $1.57B | $1.54B | $1.43B |
| Operating income | $750.2M | $702.1M | $630.9M | $502.2M | $509.0M |
| Net income | $552.5M | $513.7M | $631.3M | $353.4M | $369.4M |
| Diluted EPS | $3.13 | $2.85 | $3.41 | $1.88 | $1.91 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
SCHEDULE 13G2026-05-15
View on EDGAR →10-Q2026-05-08
View on EDGAR →8-K2026-05-07
View on EDGAR →SCHEDULE 13G2026-04-29
View on EDGAR →SCHEDULE 13G2026-04-29
View on EDGAR →8-K2026-04-29
View on EDGAR →42026-04-27
View on EDGAR →42026-04-27
View on EDGAR →Go deeper on G
Search Genpact LTD’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.